



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

12<sup>h</sup> May, 2014

The Manager – Operations & Listing  
Corporate Relationship Department

**BSE Limited**

Rotunda Building, P J Towers

Dalal Street, Fort

Mumbai - 400001

**BSE Scrip Code: 531207**

**Subject: Outcome of the Meeting of the Board of Directors**

Dear Sir:

This is to inform you that in the meeting of the Board of Directors held on Monday, 12<sup>th</sup> day of May, 2014 at the Registered Office of the Company, following resolutions were passed:

1. The Board considered and approved the Audited Financial Results for the year and quarter ended 31<sup>st</sup> March, 2014 as per clause 41 of the listing Agreement.
2. The Board took note of the Auditor's Report as placed by the Auditor of the Company.

You are kindly requested to take the information on record.

Thanking you,

Sincerely,

**For Raymed Labs Ltd.**

**Ajai Goyal**

Managing Director

Encl: as stated

Cc: **Delhi Stock Exchange Limited**  
**Uttar Pradesh Stock Exchange Limited**  
**Ahmedabad Stock Exchange Limited**  
**Jaipur Stock Exchange Limited**

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :  
GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)  
e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com  
Tel. 0132-3242000

## Audited Financial Results for the Quarter/Year Ended on March 31, 2014

PART I						Rs. in Lacs	
PART I	Particulars	3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months in the Previous Year Ended	Current Year Ended	Previous Year Ended	
		31-03-2014	31-12-2013	31-03-2013	31-03-2014	31-03-2013	
		Audited	Unaudited	Audited	Audited	Audited	
1	<b>Income from Operations</b>						
	(a) Net Sales / Income from Operations (Net of excise duty)	-	-	-	-	-	
	(b) Other Operating Income	-	-	0.03	-	0.09	
	<b>Total Income from Operations (net)</b>	-	-	0.03	-	0.09	
2	<b>Expenses</b>						
	(a) Cost of materials consumed	-	-	-	-	-	
	(b) Purchase of stock-in-trade	-	-	-	-	-	
	Changes in inventories of finished goods,						
	(c) work-in-progress and stock-in-trade	-	-	-	-	-	
	(d) Employee expenses & benefits	0.42	0.42	0.42	1.68	1.50	
	(e) Depreciation and amortisation expense	-0.12	-	0.22	0.19	1.36	
	(f) Other expenses	0.38	0.15	0.60	1.52	1.66	
	<b>Total Expenses</b>	0.68	0.57	1.24	3.39	4.52	
3	<b>Profit/(Loss) from Operations before other Income, Finance costs and Exceptional Items (1-2)</b>	-0.68	-0.57	-1.21	-3.39	-4.43	
4	Other Income	0.54	-	-	2.13	-	
5	<b>Profit/Loss from ordinary activities before finance costs and exceptional Items (3+4)</b>	-0.14	-0.57	-1.21	-1.26	-4.43	
6	Finance Costs	-	-	-	-	-	
7	<b>Profit/Loss from ordinary activities after finance costs but before exceptional items (5-6)</b>	-0.14	-0.57	-1.21	-1.26	-4.43	
8	Exceptional Items	3.49	-	1.49	3.66	2.13	
9	<b>Profit/Loss from Ordinary Activities before tax (7-8)</b>	-3.64	-0.57	-2.70	-4.92	-6.56	
10	Tax Expense	-	-	-	-	-	
11	<b>Net Profit/ Loss from Ordinary Activities after Tax (9-10)</b>	-3.64	-0.57	-2.70	-4.92	-6.56	
12	Extraordinary Item (net of tax expense)	-	-	-	-	-	
13	<b>Net Profit/ Loss for the period (11-12)</b>	-3.64	-0.57	-2.70	-4.92	-6.56	
17	Paid up Equity Share Capital (Face Value Rs.10/- per share)	427.35	427.35	427.35	427.35	427.35	
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	
19 i	<b>Earning Per Share (before extraordinary items)</b>	-0.09	-0.01	-0.06	-0.12	-0.15	
19 ii	<b>Earning Per Share (after extraordinary items)</b>	-0.09	-0.01	-0.06	-0.12	-0.15	

*Life is Precious .....and Raymed cares*



# Raymed Labs Ltd.

Manufacturers of Allopathic Medicines

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

PART II						
	Particulars	3 Months Ended 31-03-2014	Preceding 3 Months Ended 31-12-2013	Corresponding 3 Months in the Previous Year Ended 31-03-2013	Current Year Ended 31-03-2014	Previous Year Ended 31-03-2013
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding					
	- Number of shares	3,061,450	3,061,450	2,939,850	3,061,450	2,939,850
	- Percentage of shareholding	71.64%	71.64%	68.79%	71.64%	68.79%
2	Promoters and promoter group Shareholding					
a)	Pledged/Encumbered					
	- Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a% of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered					
	- Number of Shares	1,212,050	1,212,050	1,333,650	1,212,050	1,333,650
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a% of the total share capital of the company)	28.36%	28.36%	31.21%	28.36%	31.21%

B	INVESTOR COMPLAINTS	3 Months Ended (31/03/2014)
	Pending at the beginning of the quarter	0
	Received during the quarter	0
	Disposed of during the quarter	0
	Remaining unresolved at the end of the quarter	0

**Notes:**

- 1 The audited financial statements for the quarter and year ended on March 31, 2014 as reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 12, 2014. The information presented above is extracted from the financial statement.
- 2 The figures of the last quarter of current and corresponding previous year are the balancing figures between the audited figures of the full financial year and published year to date figures upto the third quarter of the financial year.
- 3 EPS has been calculated in accordance with AS-20 issued by ICAI.
- 4 The Business of the Company falls under a single segment for the purpose of Accounting Standard As-17, issued by ICAI.
- 5 Previous period/year figures have been regrouped/rearranged, wherever found necessary.
- 6 No investor complaints were pending in the beginning and end of the quarter ended March 2014.

For Raymed Labs Limited

*Ajai Goyal*

Ajai Goyal  
Managing Director

Place: Saharanpur

Date: 12-05-2014

*Life is Precious .....and Raymed cares*



# **Raymed Labs Ltd.**

**Manufacturers of Allopathic Medicines**

CIN: L24111UP1992PLC014240

REGISTERED OFFICE, HEAD OFFICE & FACTORY :

GREENLAND COMPLEX, DEHRADUN ROAD, SAHARANPUR-247001 (U.P.)

e-mail : raymedlabs@rediffmail.com website : www.raymedlabs.com

Tel. 0132-3242000

## Statement of Assets and Liabilities

Rs. in Lacs

	As at year end 31-03-2014	As at previous year end 31-03-2013
Particulars	Audited	Audited
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' Funds</b>		
(a) Share Capital	427.35	427.35
(b) Reserves and Surplus	-	-
(c) Money Received Against Share Warrants	-	-
Sub-total - Shareholders' Funds	427.35	427.35
<b>2 Share Application Money Pending Allotment</b>		
<b>3 Minority Interest</b>		
<b>4 Non-Current Liabilities</b>		
(a) Long-Term Borrowings		
(b) Deferred Tax Liabilities (net)		
(c) Other Long-Term Liabilities		
(d) Long-Term Provisions		
Sub-total - Non-Current Liabilities		
<b>5 Current Liabilities</b>		
(a) Short-Term Borrowings	196.16	214.60
(b) Trade Payables	-	-
(c) Other Current Liabilities	4.96	3.70
(d) Short-Term Provisions	-	-
Sub-total - Current Liabilities	201.12	218.30
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>628.47</b>	<b>645.65</b>
<b>B ASSETS</b>		
<b>1 Non-Current Assets</b>		
(a) Fixed Assets	20.20	23.74
(b) Goodwill on Consolidation	-	-
(c) Non-current Investments	-	-
(d) Deferred Tax Assets (net)	-	-
(e) Long-term Loans and Advances	-	-
(f) Other Non-current Assets	-	-
Sub-total - Non-Current Assets	20.20	23.74
<b>2 Current Assets</b>		
(a) Current Investments	-	-
(b) Inventories	-	0.15
(c) Trade Receivables	2.49	10.98
(d) Cash and Cash Equivalents	0.08	3.68
(e) Short-term Loans and Advances	-	6.25
(f) Other Current Assets	7.10	7.19
Sub-total - Current Assets	9.68	28.25
<b>TOTAL - ASSETS</b>	<b>29.88</b>	<b>51.99</b>
<b>3 Profit and Loss Account</b>	598.59	593.66
<b>TOTAL APPLICATION OF FUNDS</b>	<b>628.47</b>	<b>645.65</b>

For Raymed Labs Limited

Ajai Goyal

Ajai Goyal  
Managing Director

Place: Saharanpur

Date: 12.05.2014.

Life is Precious .....and Raymed cares

**DEEPAK GUPTA**  
CHARTERED ACCOUNTANTS  
Bhawani Niwas, Near Mukul School  
Pratap Nagar, Raiwala  
Saharanpur- 247001

Ph (O): 0132-2647640

(M): 9412230648

Email id: deepakfirst@rediffmail.com

Auditor's Report on Quarterly and Year Ending on 31/03/2014 Financial Results of the M/S RAYMED LABS LTD, Pursuant to the Clause 41 of the Listing Agreement

To  
Board of Directors of M/S RAYMED LABS LTD,

I have audited the quarterly financial results of M/S RAYMED LABS LIMITED for the quarter ended on 31/03/2014 and the year ended on 31/03/2014, attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by me. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. My responsibility is to express an opinion on these financial results based on my audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, issued pursuant to the Companies (Accounting Standards) Rules, 2006 as per section 211(3C) of the Companies Act, 1956 or by the Institute of Chartered Accountants of India<sup>5</sup> and other accounting principles generally accepted in India.

I conducted my audit in accordance with the auditing standards generally accepted in India. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. I believe that my audit provides a reasonable basis for my opinion.

In my opinion and to the best of my information and according to the explanations given to me these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit/ loss and other financial information for the quarter ended on 31/03/2014 as well as the year to date results.

Further, I also report that I have, on the basis of the books of account and other records and information and explanations given to me by the management, also verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

Place of signature : Saharanpur  
Date : 12/05/2014



CA Deepak Gupta  
Chartered Accountants  
*Deepak Gupta*  
Signature  
Membership Number 074641